Subject(s)
COVID-19 , Drug Eruptions , Lichen Planus , Vaccines , Antibodies, Viral , COVID-19/prevention & control , Drug Eruptions/etiology , Humans , RNA, Messenger , SARS-CoV-2ABSTRACT
A fixed drug eruption (FDE) is a common cutaneous adverse drug reaction which occurs following administration of an offending drug. The aim of this review is to provide an update on the list of drugs causing FDE, with a focus on emerging drug culprits reported since the start of the century. Across published literature, triggers for FDE are widely varied. The most frequently implicated drugs include analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs] and paracetamol) and antibiotics. Co-trimoxazole is perhaps the most well described single agent. Since the start of the century there have been over 200 drugs named in case reports on FDE. Newer, novel agents of note include cyclooxygenase-2 specific inhibitors, fluconazole, and phosphodiesterase 5 inhibitors. Other implicated drugs include vaccines, such as various SARS-CoV-2 vaccines. Drugs incriminated in FDE vary based on the geographical region studied and prescribing patterns at a given time. Newer drugs continue to enter the market and are playing an increasing role in the field of FDE. Awareness of rarer culprits and emerging novel agents can help identify a trigger, allowing for prompt withdrawal of the causative agent, preventing recurrence.
Subject(s)
COVID-19 Vaccines , COVID-19 , Drug Eruptions , Humans , Acetaminophen/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , COVID-19 Vaccines/adverse effects , Cyclooxygenase 2/therapeutic use , Drug Eruptions/diagnosis , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Fluconazole/therapeutic use , Phosphodiesterase 5 Inhibitors/therapeutic use , SARS-CoV-2 , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effectsSubject(s)
COVID-19 , Drug Eruptions , BNT162 Vaccine , Drug Eruptions/diagnosis , Drug Eruptions/etiology , HumansSubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug Eruptions/etiology , Adult , Aged , Aged, 80 and over , BNT162 Vaccine/adverse effects , ChAdOx1 nCoV-19/adverse effects , Drug Eruptions/drug therapy , Drug Eruptions/pathology , Drug Eruptions/physiopathology , Female , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Male , Middle Aged , Phenotype , SARS-CoV-2 , Young AdultABSTRACT
Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. We analysed the incidence of FVP-induced cutaneous adverse reactions (CARs) in patients infected with COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, a principal centre of emerging infectious disease in Thailand, and who presented with cutaneous eruption following FVP prescription. We identified five cases of FVP-induced CARs: two patients with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. The median interval between FVP treatment and rash occurrence was 7 days and the mean duration of the rash was 5 days. This report highlights that FVP can induce CARs, particularly eruptions, in COVID-19-infected patients. Clinicians should be aware of this possible drug-related allergy, and it should be excluded as a cause of rash during FVP treatment of COVID-19.
Subject(s)
Amides/adverse effects , Antiviral Agents/adverse effects , Drug Eruptions/etiology , Pyrazines/adverse effects , Urticaria/chemically induced , Adult , Amides/administration & dosage , Antiviral Agents/administration & dosage , Female , Humans , Middle Aged , Pyrazines/administration & dosage , Young Adult , COVID-19 Drug TreatmentABSTRACT
We present an interesting and novel case of a de novo generalized pustular psoriasis following administration of first dose of Oxford-AstraZeneca COVID-19 vaccine in a patient with no pre-existing psoriasis or any previous dermatological issue.
Subject(s)
COVID-19/prevention & control , ChAdOx1 nCoV-19/adverse effects , Drug Eruptions/etiology , Psoriasis/chemically induced , Aged , Female , Humans , Psoriasis/drug therapy , SARS-CoV-2ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a significant health problem globally. The virus has spread widely and become a global pandemic. The pathophysiology for SARS-CoV-2 has not been explained clearly. It has been associated with several multiorgan symptoms, among which its dermatological manifestations are of great interest. Primarily, there has been no report of skin features among COVID-19 patients. Nevertheless, recently there have been several reports regarding COVID-19 patients who presented with cutaneous manifestations. In the current review, we focus on the various cutaneous manifestations of COVID-19 infection.
Subject(s)
COVID-19/complications , Skin Diseases/etiology , Dermatitis, Occupational/diagnosis , Dermatitis, Occupational/etiology , Dermatitis, Occupational/pathology , Dermatitis, Occupational/therapy , Diagnosis, Differential , Drug Eruptions/diagnosis , Drug Eruptions/etiology , Drug Eruptions/pathology , Drug Eruptions/therapy , Humans , Personal Protective Equipment/adverse effects , SARS-CoV-2 , Skin Diseases/diagnosis , Skin Diseases/pathology , Skin Diseases/therapy , COVID-19 Drug TreatmentABSTRACT
Evidence is accumulating that COVID-19 vaccines might induce or exacerbate autoimmune rheumatic diseases. The currently available COVID-19 vaccines include mRNA and recombinant adenoviral vector vaccines, both encoding SARS-CoV-2 spike protein production as the primary target for neutralizing antibodies. We report a case of subacute cutaneous lupus erythematosus (SCLE) following mRNA vaccination with the Pfizer mRNA vaccine BNT162b2, and summarize the current literature on CLE occurring after COVID-19 vaccination.
Subject(s)
BNT162 Vaccine/adverse effects , COVID-19/prevention & control , Drug Eruptions/etiology , Lupus Erythematosus, Cutaneous/chemically induced , Ad26COVS1/adverse effects , Aged , ChAdOx1 nCoV-19/adverse effects , Humans , Male , SARS-CoV-2 , Vaccination/adverse effectsSubject(s)
BNT162 Vaccine/adverse effects , Drug Eruptions/etiology , Skin Diseases, Vesiculobullous/chemically induced , Aged , Aged, 80 and over , COVID-19/prevention & control , Drug Eruptions/metabolism , Drug Eruptions/pathology , Humans , Male , Skin Diseases, Vesiculobullous/metabolism , Skin Diseases, Vesiculobullous/pathologyABSTRACT
This is a case of symmetrical drug-related intertriginous and flexural exanthema-like eruption following ChAdOx1 nCoV-19 (AstraZeneca-Oxford) vaccination. Investigations, including repeated skin swabs, ruled out an infectious cause. He was subsequently treated with oral prednisolone, which led to a resolution of his symptoms.
Subject(s)
COVID-19/prevention & control , ChAdOx1 nCoV-19/adverse effects , Drug Eruptions/etiology , Exanthema/chemically induced , Intertrigo/chemically induced , Humans , Male , Middle Aged , SARS-CoV-2 , Vaccination/adverse effectsSubject(s)
BNT162 Vaccine/adverse effects , Drug Eruptions/diagnosis , Drug Eruptions/etiology , Immune Checkpoint Inhibitors/adverse effects , Ipilimumab/adverse effects , Nivolumab/adverse effects , Anti-Bacterial Agents/adverse effects , COVID-19/prevention & control , Female , Humans , Melanoma/drug therapy , Middle Aged , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effectsABSTRACT
We describe a case of a pityriasis rubra pilaris (PRP)-like eruption occurring following administration of the Pfizer-Biontech mRNA COVID-19 vaccine, with worsening of the condition following the second dose. To our knowledge, this is the first reported case of a PRP-like eruption as a cutaneous adverse event of the Pfizer-Biontech mRNA COVID-19 vaccine.